FDA approves abemaciclib with endocrine therapy for early breast cancer


13 October 2021 - On 12 October 2021, the FDA approved abemaciclib (Verzenio, Eli Lilly) with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment of adult patients with hormone receptor positive, human epidermal growth factor receptor 2 negative, node-positive, early breast cancer at high risk of recurrence and a Ki-67 score ≥20%, as determined by an FDA approved test. 

This is the first CDK 4/6 inhibitor approved for adjuvant treatment of breast cancer.

Read FDA News

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , US